Daphne Karydas - 13 Nov 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
13 Nov 2025
Net transactions value
-$536,797
Form type
4
Filing time
13 Nov 2025, 19:01:24 UTC
Previous filing
13 Jun 2025
Next filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Karydas Daphne Director 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR /s/ Adam Levy, Attorney-in-fact 13 Nov 2025 0001816952

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $153,000 +15,000 $10.20 15,000 13 Nov 2025 Direct
transaction MLYS Common Stock Sale $463,351 -10,115 -67% $45.81 4,885 13 Nov 2025 Direct F1
transaction MLYS Common Stock Sale $226,446 -4,885 -100% $46.36 0 13 Nov 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -15,000 -46% $0.000000 17,900 13 Nov 2025 Common Stock 15,000 $10.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.19 to $46.18. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.19 to $46.70. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The stock option vests in 12 monthly installments following the date of grant.